BRISTOL MYERS SQUIBB CO BMY
Pharmaceutical Preparations · NYSE, NYSE
Umsatz
$45.01B
-2.5% Jahresübergangsrate
Nettoerlös
$8.03B
+26.8% Jahresübergangsrate
Gesamtvermögen
$92.60B
-2.7% Jahresübergangsrate
EPS
3.86
+30.8% Jahresübergangsrate
Advertisement
Einkommensrechnung
| Zeitraum | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Revenues | $35.69B | $23.47B | $11.20B | $45.01B | $35.96B | $24.07B | $11.87B | $46.16B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| R&D Expense | $7.37B | $4.84B | $2.26B | $9.30B | $7.97B | $5.59B | $2.69B | $9.51B |
| SG&A Expense | $5.09B | $3.30B | $1.58B | $7.77B | $6.28B | $4.29B | $2.37B | $7.81B |
| Operating Income (Loss) | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Net Income (Loss) | $5.97B | $3.77B | $2.46B | $8.03B | $-9.02B | $-10.23B | $-11.91B | $6.33B |
| EPS (Diluted) | 2.93 | 1.85 | 1.20 | 3.86 | -4.45 | -5.05 | -5.89 | 2.95 |
Bilanz
| Zeitraum | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $90.04B | $90.04B | $90.04B | $92.60B | $92.60B | $92.60B | $92.60B | $95.16B |
| Current Assets | $29.39B | $29.39B | $29.39B | $29.78B | $29.78B | $29.78B | $29.78B | $31.77B |
| Cash & Equivalents | $10.21B | $10.21B | $10.21B | $10.35B | $10.35B | $10.35B | $10.35B | $11.46B |
| Accounts Receivable | $9.59B | $9.59B | $9.59B | $9.01B | $9.01B | $9.01B | $9.01B | $8.88B |
| Inventory | $2.69B | $2.69B | $2.69B | $2.56B | $2.56B | $2.56B | $2.56B | $2.66B |
| PP&E (Net) | $7.54B | $7.54B | $7.54B | $7.14B | $7.14B | $7.14B | $7.14B | $6.65B |
| Goodwill | $21.75B | $21.75B | $21.75B | $21.17B | $21.72B | $21.72B | $21.72B | $21.15B |
| Total Liabilities | $71.53B | $71.53B | $71.53B | $76.22B | $76.22B | $76.22B | $76.22B | $65.67B |
| Current Liabilities | $23.42B | $23.42B | $23.42B | $23.77B | $23.77B | $23.77B | $23.77B | $22.26B |
| Accounts Payable | $3.58B | $3.58B | $3.58B | $3.60B | $3.60B | $3.60B | $3.60B | $3.26B |
| Long-Term Debt | $44.83B | $44.83B | $44.83B | $49.43B | $49.43B | $49.43B | $49.43B | $39.53B |
| Stockholders Equity | $18.47B | $18.47B | $18.47B | $16.34B | $16.34B | $16.34B | $16.34B | $29.43B |
Kassenfluss
| Zeitraum | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 FY | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 FY |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $12.18B | $5.87B | $1.95B | $13.86B | $10.75B | $5.16B | $2.83B | $13.07B |
| Investing Cash Flow | $-2.67B | $-972.00M | $-499.00M | $-2.29B | $-21.16B | $-20.94B | $-19.62B | $-1.06B |
| Financing Cash Flow | $-4.32B | $-2.83B | $-993.00M | $-9.42B | $6.77B | $10.62B | $14.64B | $-16.96B |
| Stock Repurchases | — | — | — | $5.16B | — | — | — | $8.00B |
Ähnliche Firmen
AbbVie Inc.
ABBV
ABBOTT LABORATORIES
ABT
JOHNSON & JOHNSON
JNJ
ELI LILLY & Co
LLY
Merck & Co., Inc.
MRK
PFIZER INC
PFE
REGENERON PHARMACEUTICALS, INC.
REGN
VERTEX PHARMACEUTICALS INC / MA
VRTX
Mehr erfahren
How to Find Any SEC Filing in Two MinutesCash-Flow Quality: Profit Is an Opinion, Cash Is a FactValuation Basics: P/E, P/S and What They Actually Tell YouDividends: How Companies Pay Shareholders and How to Read ThemHow to Read a 10-K Annual Report (Without Falling Asleep)Understanding Earnings Per Share (EPS)How to Read a Cash Flow StatementHow to Read a Balance SheetHow to Read an Income Statement
Daten stammen aus der öffentlichen Datenbank des US-amerikanischen SEC EDGAR. Diese Seite bietet keine Anlageberatung.